Active	Status	Sponsor type	Region	Phase	Filter
6 Active 1 Inactive 7 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   - « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   Show only changed items Enrollment:

Advanced Filters

6 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Anti-5T4 CAR-NK Cell Therapy / Imbioray Bio
NCT05194709: Study of Anti-5T4 CAR-NK Cell Therapy in Advanced Solid Tumors	Recruiting	1	40	RoW	Anti-CAR-NK Cells	Wuxi People's Hospital, Imbioray (Hangzhou) Biomedicine Co., Ltd.	Advanced Solid Tumors	12/22	12/22
IBR854 / Imbioray Bio
NCT05137275: Study of Anti-5T4 CAR-raNK Cell Therapy in Locally Advanced or Metastatic Solid Tumors	Recruiting	1	56	RoW	Anti-5T4 CAR-raNK Cells	Shanghai East Hospital, Imbioray (Hangzhou) Biomedicine Co., Ltd.	Locally Advanced or Metastatic Solid Tumors	04/23	05/23
NCT06001684: Phase 1 Study of IBR854 in Locally Advanced Or Metastatic Solid Tumors	Recruiting	1	18	RoW	IBR854 Cell Injection	Imbioray (Hangzhou) Biomedicine Co., Ltd.	Solid Tumors	09/24	12/24
IBR733 / Imbioray Bio
NCT05215015: Study of Anti-CD33/CLL1 CAR-NK in Acute Myeloid Leukemia	Recruiting	1	18	RoW	Anti-CD33/CLL1 CAR-NK Cells	Wuxi People's Hospital, Imbioray (Hangzhou) Biomedicine Co., Ltd.	Acute Myeloid Leukemia	11/22	11/22
NCT06234904: Study of IBR733 Cell Injection in Acute Myeloid Leukemia	Not yet recruiting	1	18	RoW	IBR733 Cell Injection	Imbioray (Hangzhou) Biomedicine Co., Ltd., The First Affiliated Hospital of Soochow University	Acute Myeloid Leukemia	02/25	08/25
IBR900 / Imbioray Bio
NCT05411757: IBR900 Cell Injection Combined With Lenvatinib or Bevacizumab in the Treatment of Advanced Primary Liver Cancer	Not yet recruiting	1	12	NA	IBR900 combined with Lenvatinib, IBR900 combined with Bevacizumab	Shandong Public Health Clinical Center, Imbioray (Hangzhou) Biomedicine Co., Ltd.	Advanced Primary Liver Cancer	06/23	12/23

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Anti-5T4 CAR-NK Cell Therapy / Imbioray Bio
NCT05194709: Study of Anti-5T4 CAR-NK Cell Therapy in Advanced Solid Tumors	Recruiting	1	40	RoW	Anti-CAR-NK Cells	Wuxi People's Hospital, Imbioray (Hangzhou) Biomedicine Co., Ltd.	Advanced Solid Tumors	12/22	12/22
IBR854 / Imbioray Bio
NCT05137275: Study of Anti-5T4 CAR-raNK Cell Therapy in Locally Advanced or Metastatic Solid Tumors	Recruiting	1	56	RoW	Anti-5T4 CAR-raNK Cells	Shanghai East Hospital, Imbioray (Hangzhou) Biomedicine Co., Ltd.	Locally Advanced or Metastatic Solid Tumors	04/23	05/23
NCT06001684: Phase 1 Study of IBR854 in Locally Advanced Or Metastatic Solid Tumors	Recruiting	1	18	RoW	IBR854 Cell Injection	Imbioray (Hangzhou) Biomedicine Co., Ltd.	Solid Tumors	09/24	12/24
IBR733 / Imbioray Bio
NCT05215015: Study of Anti-CD33/CLL1 CAR-NK in Acute Myeloid Leukemia	Recruiting	1	18	RoW	Anti-CD33/CLL1 CAR-NK Cells	Wuxi People's Hospital, Imbioray (Hangzhou) Biomedicine Co., Ltd.	Acute Myeloid Leukemia	11/22	11/22
NCT06234904: Study of IBR733 Cell Injection in Acute Myeloid Leukemia	Not yet recruiting	1	18	RoW	IBR733 Cell Injection	Imbioray (Hangzhou) Biomedicine Co., Ltd., The First Affiliated Hospital of Soochow University	Acute Myeloid Leukemia	02/25	08/25
IBR900 / Imbioray Bio
NCT05411757: IBR900 Cell Injection Combined With Lenvatinib or Bevacizumab in the Treatment of Advanced Primary Liver Cancer	Not yet recruiting	1	12	NA	IBR900 combined with Lenvatinib, IBR900 combined with Bevacizumab	Shandong Public Health Clinical Center, Imbioray (Hangzhou) Biomedicine Co., Ltd.	Advanced Primary Liver Cancer	06/23	12/23